{"id":25193,"date":"2022-10-11T16:36:00","date_gmt":"2022-10-11T08:36:00","guid":{"rendered":"https:\/\/flcube.com\/?p=25193"},"modified":"2025-02-03T16:45:06","modified_gmt":"2025-02-03T08:45:06","slug":"harbour-biomed-licenses-batoclimab-to-cspcs-nbp-pharma-for-greater-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=25193","title":{"rendered":"Harbour BioMed Licenses Batoclimab to CSPC’s NBP Pharma for Greater China"},"content":{"rendered":"\n

Harbour BioMed (HKG: 2142<\/a>), a biotech company operating out of the United States, the Netherlands, and Suzhou (China), has announced a licensing agreement with CSPC Pharmaceutical Group Co., Ltd\u2019s (HKG: 1093<\/a>) wholly-owned subsidiary Shijiazhuang Pharma Group NBP Pharmaceutical (Shijiazhuang) Co. Ltd. The agreement grants NBP Pharma exclusive development, manufacturing, and commercialization rights to batoclimab (HBM9161) in Greater China (including mainland China, Hong Kong, Macau, and Taiwan). In return, NBP Pharma will pay Harbour Bio upwards of RMB 1 billion (USD 139 million), including RMB 150 million (USD 20.8 million) in an upfront payment and potential milestone payments, alongside tiered sales commission based on annual net sales.<\/p>\n\n\n\n

Batoclimab: Drug Profile and Development<\/strong>
Batoclimab has been shown to rapidly reduce total IgG by blocking FcRn-IgG interactions and accelerating the degradation of autoantibodies by blocking the binding of FcRn and IgG. The molecule is under development to treat a range of autoimmune diseases, including myasthenia gravis, thyroid-related ophthalmopathy, optic neuromyelitis spectrum disease, immune thrombocytopenia, chronic inflammatory demyelinating polyradiculoneuropathy, pemphigus vulgaris, and more.<\/p>\n\n\n\n

Future Outlook<\/strong>
The licensing agreement underscores Harbour BioMed’s commitment to advancing innovative treatments for autoimmune diseases. By partnering with CSPC’s NBP Pharma, Harbour BioMed aims to leverage NBP’s expertise and market presence in Greater China to bring batoclimab to patients in need. This collaboration is expected to accelerate the development and commercialization of batoclimab, ultimately improving patient outcomes.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Harbour BioMed (HKG: 2142), a biotech company operating out of the United States, the Netherlands,…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[65,30,171,190,855,916,3521],"class_list":["post-25193","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-auto-immune","tag-biotech","tag-cspc-pharmaceutical","tag-harbour-biomed","tag-hkg-1093","tag-hkg-2142","tag-nbp-pharmaceutical"],"yoast_head":"\nHarbour BioMed Licenses Batoclimab to CSPC's NBP Pharma for Greater China - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Harbour BioMed (HKG: 2142), a biotech company operating out of the United States, the Netherlands, and Suzhou (China), has announced a licensing agreement with CSPC Pharmaceutical Group Co., Ltd\u2019s (HKG: 1093) wholly-owned subsidiary Shijiazhuang Pharma Group NBP Pharmaceutical (Shijiazhuang) Co. Ltd. The agreement grants NBP Pharma exclusive development, manufacturing, and commercialization rights to batoclimab (HBM9161) in Greater China (including mainland China, Hong Kong, Macau, and Taiwan). In return, NBP Pharma will pay Harbour Bio upwards of RMB 1 billion (USD 139 million), including RMB 150 million (USD 20.8 million) in an upfront payment and potential milestone payments, alongside tiered sales commission based on annual net sales.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=25193\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Harbour BioMed Licenses Batoclimab to CSPC's NBP Pharma for Greater China\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=25193\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-11T08:36:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-03T08:45:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25193#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25193\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Harbour BioMed Licenses Batoclimab to CSPC’s NBP Pharma for Greater China\",\"datePublished\":\"2022-10-11T08:36:00+00:00\",\"dateModified\":\"2025-02-03T08:45:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25193\"},\"wordCount\":241,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"Biotech\",\"CSPC Pharmaceutical\",\"Harbour BioMed\",\"HKG: 1093\",\"HKG: 2142\",\"NBP Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25193#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25193\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=25193\",\"name\":\"Harbour BioMed Licenses Batoclimab to CSPC's NBP Pharma for Greater China - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-10-11T08:36:00+00:00\",\"dateModified\":\"2025-02-03T08:45:06+00:00\",\"description\":\"Harbour BioMed (HKG: 2142), a biotech company operating out of the United States, the Netherlands, and Suzhou (China), has announced a licensing agreement with CSPC Pharmaceutical Group Co., Ltd\u2019s (HKG: 1093) wholly-owned subsidiary Shijiazhuang Pharma Group NBP Pharmaceutical (Shijiazhuang) Co. Ltd. The agreement grants NBP Pharma exclusive development, manufacturing, and commercialization rights to batoclimab (HBM9161) in Greater China (including mainland China, Hong Kong, Macau, and Taiwan). In return, NBP Pharma will pay Harbour Bio upwards of RMB 1 billion (USD 139 million), including RMB 150 million (USD 20.8 million) in an upfront payment and potential milestone payments, alongside tiered sales commission based on annual net sales.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25193#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25193\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25193#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Harbour BioMed Licenses Batoclimab to CSPC’s NBP Pharma for Greater China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Harbour BioMed Licenses Batoclimab to CSPC's NBP Pharma for Greater China - Insight, China's Pharmaceutical Industry","description":"Harbour BioMed (HKG: 2142), a biotech company operating out of the United States, the Netherlands, and Suzhou (China), has announced a licensing agreement with CSPC Pharmaceutical Group Co., Ltd\u2019s (HKG: 1093) wholly-owned subsidiary Shijiazhuang Pharma Group NBP Pharmaceutical (Shijiazhuang) Co. Ltd. The agreement grants NBP Pharma exclusive development, manufacturing, and commercialization rights to batoclimab (HBM9161) in Greater China (including mainland China, Hong Kong, Macau, and Taiwan). In return, NBP Pharma will pay Harbour Bio upwards of RMB 1 billion (USD 139 million), including RMB 150 million (USD 20.8 million) in an upfront payment and potential milestone payments, alongside tiered sales commission based on annual net sales.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=25193","og_locale":"en_US","og_type":"article","og_title":"Harbour BioMed Licenses Batoclimab to CSPC's NBP Pharma for Greater China","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=25193","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-10-11T08:36:00+00:00","article_modified_time":"2025-02-03T08:45:06+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=25193#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=25193"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Harbour BioMed Licenses Batoclimab to CSPC’s NBP Pharma for Greater China","datePublished":"2022-10-11T08:36:00+00:00","dateModified":"2025-02-03T08:45:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=25193"},"wordCount":241,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","Biotech","CSPC Pharmaceutical","Harbour BioMed","HKG: 1093","HKG: 2142","NBP Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=25193#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=25193","url":"https:\/\/flcube.com\/?p=25193","name":"Harbour BioMed Licenses Batoclimab to CSPC's NBP Pharma for Greater China - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-10-11T08:36:00+00:00","dateModified":"2025-02-03T08:45:06+00:00","description":"Harbour BioMed (HKG: 2142), a biotech company operating out of the United States, the Netherlands, and Suzhou (China), has announced a licensing agreement with CSPC Pharmaceutical Group Co., Ltd\u2019s (HKG: 1093) wholly-owned subsidiary Shijiazhuang Pharma Group NBP Pharmaceutical (Shijiazhuang) Co. Ltd. The agreement grants NBP Pharma exclusive development, manufacturing, and commercialization rights to batoclimab (HBM9161) in Greater China (including mainland China, Hong Kong, Macau, and Taiwan). In return, NBP Pharma will pay Harbour Bio upwards of RMB 1 billion (USD 139 million), including RMB 150 million (USD 20.8 million) in an upfront payment and potential milestone payments, alongside tiered sales commission based on annual net sales.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=25193#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=25193"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=25193#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Harbour BioMed Licenses Batoclimab to CSPC’s NBP Pharma for Greater China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25193","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25193"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25193\/revisions"}],"predecessor-version":[{"id":25195,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25193\/revisions\/25195"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25193"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=25193"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=25193"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}